Evidence map›Paper›PMID 39160581›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

Areca nut-induced metabolic reprogramming and M2 differentiation promote OPMD malignant transformation.

Shyng-Shiou F Yuan, Leong-Perng Chan, Hieu D H Nguyen, Chang-Wei Su, Yuk-Kwan Chen, Jeff Yi-Fu Chen, Shigetaka Shimodaira, Stephen Chu-Sung Hu, Steven Lo, Yen-Yun Wang

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shyng-Shiou F YuanGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Leong-Perng ChanCohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hieu D H NguyenSchool of Dentistry, College of Dental Medicine, Kaohsiung Medical University, No.100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung, 80708, Taiwan.
Chang-Wei SuSchool of Dentistry, College of Dental Medicine, Kaohsiung Medical University, No.100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung, 80708, Taiwan.
Yuk-Kwan ChenSchool of Dentistry, College of Dental Medicine, Kaohsiung Medical University, No.100, Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung, 80708, Taiwan.
Jeff Yi-Fu ChenDepartment of Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan.
Shigetaka ShimodairaDepartment of Regenerative Medicine, Kanazawa Medical University, Kahoku, Ishikawa, 920-0293, Japan.
Stephen Chu-Sung HuDepartment of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
Steven LoCanniesburn Regional Plastic Surgery and Burns Unit, Glasgow, G4 0SF, UK.
Yen-Yun WangDepartment of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan. wyy@kmu.edu.tw.ORCID http://orcid.org/0000-0003-4442-4801

Funding

Kaohsiung Medical University KMU-DK(A)111005Kaohsiung Medical University KMU-DK(A)112006Kaohsiung Medical University KMU-DK(A)113002Kaohsiung Medical University KMU-TC112A03-5Kaohsiung Medical University NYCUKMU-111-I002Kaohsiung Medical University NYCU-KMU-112-I005Kaohsiung Medical University NYCUKMU-113-I002Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH109-9R42Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH110-0R43Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH111-1R37Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH112-2R42Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH-DK(A)110001Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH-DK(A)112001Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH-DK(A)113001Ministry of Education Intelligent Drug SystemsMinistry of Education Smart Biodevices (IDS2B)National Science and Technology Council NSTC 112-2314-B-037-112-MY3National Science and Technology Council NSTC 112-2314-B-037-120
6 · The paper itself

Abstract

backgroundBetel quid and its major ingredient, areca nut, are recognized by IARC as major risk factors in oral cancer development. Areca nut extract (ANE) exposure has been linked to OPMD progression and malignant transformation to OSCC. However, the detailed mechanism through which ANE acts on other cell types in the oral microenvironment to promote oral carcinogenesis remains elusive.

methodsImmunoprofiling of macrophages associated with OPMD and OSCC was carried out by immunohistochemical and immunofluorescence staining. Phosphokinase and cytokine arrays and western blotting were performed to determine the underlying mechanisms. Transwell assays were used to evaluate the migration-promoting effect of ANE. Hamster model was finally applied to confirm the in vivo effect of ANE.

resultsWe reported that M2 macrophages positively correlated with oral cancer progression. ANE induced M2 macrophage differentiation, CREB phosphorylation and VCAM-1 secretion and increased mitochondrial metabolism. Conditioned medium and VCAM-1 from ANE-treated macrophages promoted migration and mesenchymal phenotypes in oral precancer cells. In vivo studies showed that ANE enhanced M2 polarization and related signaling pathways in the oral buccal tissues of hamsters.

conclusionOur study provides novel mechanisms for areca nut-induced oral carcinogenesis, demonstrating that areca nut promotes M2 macrophage differentiation and secretion of oncogenic cytokines that critically activate malignant transformation of oral premalignant cells.

Indexed as

ArecaCell DifferentiationCell Transformation, NeoplasticMacrophagesMouth NeoplasmsAnimalsCricetinaeDisease Models, AnimalHumansMaleMetabolic ReprogrammingNutsAreca nutMacrophageMitochondrial metabolismOPMDOSCC

Identifiers

PMID39160581
PMCPMC11334407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.